March 19, 2026 /PRNewswire/ — Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical enterprise dedicated to advancing innovative therapeutics in inflammation and immunology, alongside its subsidiary Scinai Biopharma Services Ltd., a rapidly expanding contract development and manufacturing organisation (CDMO), has announced its participation in BIO-Europe Spring® 2026. This significant event is scheduled to take place from March 23 to 25 in Lisbon, Portugal.
This conference marks Scinai’s inaugural major international engagement following its recent acquisition of Recipharm Israel, coupled with a strategic collaboration with Recipharm. This acquisition signifies a notable enhancement of Scinai’s development and manufacturing capabilities.
The Scinai delegation for the event will feature:
- Amir Reichman, Chief Executive Officer, representing Scinai Immunotherapeutics’ R&D initiatives
- Solomon Gahtan, Business Development & Alliance Management, Biologics
- Dr. Helen Domeshek, Business Development & Alliance Management, Small Molecules
- Mr. Gahtan and Dr. Domeshek will also represent Scinai Biopharma Services Ltd., the Company’s CDMO subsidiary.
Throughout the conference, the team aims to engage with pharmaceutical and biotechnology companies, investors, and potential clients to further both Scinai’s innovative research and development pipeline and its integrated CDMO offerings.
Expanding a Differentiated Integrated CDMO Platform
Scinai Biopharma Services Ltd. provides a unique, integrated CDMO platform that supports biotechnology and pharmaceutical companies from the early development phase through to commercial supply. The operational model is anchored on three strategic pillars:
- A cGMP biologics development and manufacturing site located in Jerusalem
- A cGMP small-molecule API development and manufacturing site in Yavne, recently acquired from Recipharm
- A strategic commercial collaboration with Recipharm
This framework positions Scinai as an exceptional partner, effectively linking early-stage innovation with global commercial manufacturing. The collaboration with Recipharm enhances Scinai’s capabilities by providing access to additional capacity and technologies through subcontracting. This partnership also facilitates a seamless transition for clients from preclinical and clinical development to late-stage and commercial production, while aligning quality and technology transfer standards to significantly mitigate execution risks and expedite timelines.
At BIO-Europe Spring, Scinai will focus on attracting clients in need of flexible and high-quality development and manufacturing solutions with a clear and scalable path to commercialization.
Advancing a Robust Pipeline of Antibody-Based Immunotherapies
Scinai will also present its expanding pipeline of innovative antibody-based therapeutics aimed at addressing autoimmune and inflammatory diseases, with a particular emphasis on dermatology. This pipeline is underpinned by assets licensed from the Max Planck Society, University Medical Center Göttingen, and PinCell S.r.l.
The company actively seeks strategic partnerships, collaborative development opportunities, and licensing agreements with pharmaceutical and biotechnology enterprises to advance its therapeutic pipeline.
Amir Reichman, Chief Executive Officer of Scinai, remarked, “BIO-Europe Spring marks an important milestone for Scinai as we present our expanded capabilities following the Recipharm transaction. We are uniquely positioned to partner with biotech and pharmaceutical companies across the entire product lifecycle, from early-stage development through clinical trials to commercial manufacturing, while also advancing a distinct pipeline of immunology therapeutics. We look forward to engaging with partners who are seeking both innovation and effective execution.”
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company focused on developing innovative immunology therapies. The Company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l. Scinai also owns Scinai Biopharma Services Ltd., a contract development and manufacturing organisation (CDMO) that provides development and manufacturing services to biotechnology and pharmaceutical companies.
For more information, please visit: www.scinai.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined by the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws. These statements include, but are not limited to, Scinai’s participation in BIO-Europe Spring® 2026, its ability to advance its R&D pipeline, execute on business development opportunities, and expand its CDMO capabilities. These forward-looking statements are built on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Detailed information regarding these risks is included in the Company’s filings with the U.S. Securities and Exchange Commission.
Forward-looking statements are valid only as of the date of this press release. The Company assumes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise.